106 related articles for article (PubMed ID: 38766999)
1. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
[TBL] [Abstract][Full Text] [Related]
2. European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.
Boztug H; Sykora KW; Slatter M; Zecca M; Veys P; Lankester A; Cant A; Skinner R; Wachowiak J; Glogova E; Pötschger U; Peters C
Pediatr Blood Cancer; 2016 Jan; 63(1):139-48. PubMed ID: 26398915
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
Dinur-Schejter Y; Krauss AC; Erlich O; Gorelik N; Yahel A; Porat I; Weintraub M; Stein J; Zaidman I; Stepensky P
Pediatr Blood Cancer; 2015 Feb; 62(2):299-304. PubMed ID: 25284797
[TBL] [Abstract][Full Text] [Related]
5. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
6. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
8. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Nemecek ER; Guthrie KA; Sorror ML; Wood BL; Doney KC; Hilger RA; Scott BL; Kovacsovics TJ; Maziarz RT; Woolfrey AE; Bedalov A; Sanders JE; Pagel JM; Sickle EJ; Witherspoon R; Flowers ME; Appelbaum FR; Deeg HJ
Biol Blood Marrow Transplant; 2011 Mar; 17(3):341-50. PubMed ID: 20685259
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Baronciani D; Depau C; Targhetta C; Derudas D; Culurgioni F; Tandurella I; Latte G; Palmas A; Angelucci E
Hematol Oncol; 2016 Mar; 34(1):17-21. PubMed ID: 25626861
[TBL] [Abstract][Full Text] [Related]
10. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience.
Slatter MA; Rao K; Abd Hamid IJ; Nademi Z; Chiesa R; Elfeky R; Pearce MS; Amrolia P; Worth A; Flood T; Abinun M; Hambleton S; Qasim W; Gaspar HB; Cant AJ; Gennery AR; Veys P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):529-536. PubMed ID: 29155317
[TBL] [Abstract][Full Text] [Related]
11. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
12. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
13. High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study.
van der Stoep MYEC; Bertaina A; Ten Brink MH; Bredius RG; Smiers FJ; Wanders DCM; Moes DJAR; Locatelli F; Guchelaar HJ; Zwaveling J; Lankester AC
Br J Haematol; 2017 Dec; 179(5):772-780. PubMed ID: 29048102
[TBL] [Abstract][Full Text] [Related]
14. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
Slatter MA; Rao K; Amrolia P; Flood T; Abinun M; Hambleton S; Nademi Z; Goulden N; Davies G; Qasim W; Gaspar HB; Cant A; Gennery AR; Veys P
Blood; 2011 Apr; 117(16):4367-75. PubMed ID: 21325599
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
18. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.
Lehmberg K; Albert MH; Beier R; Beutel K; Gruhn B; Kröger N; Meisel R; Schulz A; Stachel D; Woessmann W; Janka G; Müller I
Haematologica; 2014 Jan; 99(1):180-4. PubMed ID: 24162790
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases.
Slatter MA; Boztug H; Pötschger U; Sykora KW; Lankester A; Yaniv I; Sedlacek P; Glogova E; Veys P; Gennery AR; Peters C;
Bone Marrow Transplant; 2015 Dec; 50(12):1536-41. PubMed ID: 26259076
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial.
Burroughs LM; Nemecek ER; Torgerson TR; Storer BE; Talano JA; Domm J; Giller RH; Shimamura A; Delaney C; Skoda-Smith S; Thakar MS; Baker KS; Rawlings DJ; Englund JA; Flowers ME; Deeg HJ; Storb R; Woolfrey AE
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1996-2003. PubMed ID: 25196857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
